ViiV Healthcare Advances Ultra-Long-Acting HIV Treatments with New CROI 2026 Data
Event summary
- ViiV Healthcare presented new data on ultra-long-acting HIV treatments at CROI 2026, including VH184, a third-generation integrase inhibitor with potential for four-month dosing intervals.
- Interim results from the EMBRACE study showed 12-month HIV suppression with lotivibart and cabotegravir long-acting (CAB LA).
- Late-breaking results from the VOLITION study provided updates on early switching to CAB+RPV LA in treatment-naïve adults.
- Real-world data from the OPERA cohort analyzed virologic outcomes by BMI and four-year follow-up results for individuals initiating CAB+RPV LA.
The big picture
ViiV Healthcare's focus on ultra-long-acting HIV treatments aligns with the industry's shift toward more convenient, patient-centric therapies. The company's integrase inhibitor pipeline positions it to lead in extending dosing intervals, potentially reshaping HIV treatment and prevention landscapes. The strategic emphasis on real-world data and diverse populations underscores ViiV's commitment to addressing unmet needs in HIV care.
What we're watching
- Pipeline Progress
- The pace at which VH184 and other ultra-long-acting candidates advance through clinical trials will determine ViiV's ability to extend dosing intervals beyond current standards.
- Market Adoption
- Whether real-world effectiveness data for CAB LA in prevention and treatment can drive broader uptake, particularly among high-risk populations like Black women.
- Competitive Positioning
- How ViiV's integrase inhibitor-led pipeline differentiates it from competitors like BIC/FTC/TAF in terms of resistance profiles and metabolic impacts.
Related topics